Neoadjuvant and postneoadjuvant treatment for triple negative breast cancer
- Authors: Semiglazov V.F1, Dzhelyalova M.A.1, Tseluyko A.I1, Pesotsky R.S1, Bessonov A.A1, Semiglazova T.Y.1
-
Affiliations:
- N.N. Petrov National Medical Research Center of Oncology
- Issue: Vol 27, No 11 (2020)
- Pages: 8-13
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/312868
- DOI: https://doi.org/10.18565/pharmateca.2020.11.8-13
- ID: 312868
Cite item
Abstract
Full Text
About the authors
V. F Semiglazov
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
Maryam A. Dzhelyalova
N.N. Petrov National Medical Research Center of Oncology
Email: gub.mariam@gmail.com
Oncologist, Clinical Diagnostic Department 68, Leningradskaya str., Pesochny settlement, St. Petersburg 197758, Russian Federation
A. I Tseluyko
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
R. S Pesotsky
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
A. A Bessonov
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
T. Yu Semiglazova
N.N. Petrov National Medical Research Center of OncologySt. Petersburg, Russia
References
- Masuda N., Lee S.J., Ohtani S., et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147-59. doi: 10.1056/NEJMoa1612645.
- Kuroi K, Toi M., Ohno S., et al. Prognostic significance of subtype and pathologic response in operable breast cancer; a pooled analysis of prospective neoadjuvant studies of JBCRG. Breast Cancer. 2015;22:486-95. https://doi.org/10.W07/s12282-013-0511-1
- Twelves C., Wong A., Nowacki M.P, et al. Capecitabine as Adjuvant Treatment for Stage III Colon Cancer N Engl J Med. 2005;352:2696-704. Doi: 10.1056/ NEJMoa043116.
- Bang YJ., Kim Y.W., Yang H.K., et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2019(989(9813):-15-21.doi: 10.1016/S0140-6736(11)61873-4.
- Noh S.H., Park S.R., Yang H.K., et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet. Oncol. 2014;15(12):1389-96. doi: 10.1016/S1470-2045(14)70473-5.
- Martin M, Ruiz S.A., Ruiz B.M., et al. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2000-10 Study. J Clin Oncol. 2015;33(32):3788-95. Doi: 10.1200/ JCO.2015.61.9510.
- Joensuu H., Kellolumpu-Lehtinen P.L., Huovinen R., et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol. 2012;30(1):11-8. Doi: 10.1200/ JCO.2011.35.4639.
- Blum J.L., Jones S.E., Buzdar A.U., et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17(2):485-93. Doi: 10.1200/ JCO.1999.17.2.485.
- Miles D., von Minckwitz G., Seidman A.D., et al. Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist. 2002;7(Suppl. 6):13-9.
- Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer. N Engl J Med. 2006;055:2700-40. doi: 10.1056/NEJMoa064320.
- O'Shaughnessy J., Koeppen H., Xiao Y, et al. Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine. Clin. Cancer Res. 2015;21(19):4305-11. doi: 10.1158/1078-0432. CCR-15-0636.
- Masuda N., Lee S.J., Ohtani S., et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147-59. doi: 10.1056/NEJMoa1612645.
- Toi M., Atiqur Rahman М., Bando H., Chow L.W. Thymidine phosphorylase (plateletderived endothelialcell growth factor) in cancer biology and treatment. Lancet. Oncol. 2005;6:158-66. Doi: 10.1016/ S1470-2045(05)01766-3.
- Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemothe arable HER2-positive breast cancer. N Engl J Med. 2005;050:1670-84. doi: 10.1056/NEJMoa052122.
- Sparano J.A., Zhao R., Martino S., et al. Long-term follow-up of the Е 1199 phase III trial evaluating the role of taxane and schedule in operable breast cancer. J Clin Oncol. 2015;00:2050-60. Doi: 10.1200/ JCO.2015.60.9271.
- Moebus V, Jackisch С., Lueck H.J., et al. Intense no conflicts of interest. dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study. J Oncol. 2010;28:2874-80. Doi: 10.1200/ JCO.2009.24.7643.
- Bear H.D., Tang G., Rastogi ft, et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3 randomized controlled trial. Lancet. Oncol. 2015;16:1037-48. doi: 10.1016/S1470-2045(15)00041-8.
- von Minckwitz G., Rezai M., Loibl S., et al. Capecitabine in addition to anthracycline and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol. 2010;28:2015-23. Doi: 10.1200/ JCO.2009.23.8303.
- Ohno S., Chow L.W., Sato N., et al. Randomized trial of preoperative docetaxel with or without capecitabine after 4 cycles of 5-fluorouracil-epirubicin-cyclophosphamide (FEC) in early-stage breast cancer: exploratory analyses identify Ki-67 as a predictive biomarker for response to neoadjuvant chemotherapy. Breast Cancer Res. Treat. 2013;142(1):69-80. doi: 10.1007/s10549-013-2691-y.
- Cortazar P., Zhang L., Untch M., et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384:164-72. doi: 10.1016/S0140-6736(13)62422-8.
- Symmans W.R., Peintinger R., Hatzis C., et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414-22. Doi: 10.1200/ JCO.2007.10.6823.
- Symmans W.R., Wei C., Gould R., et al. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and BreastCancer Subtype. J Clin Oncol. 2017;35:1049-doi: 10.1200/JCO.2015.63.W10. [Epub 2017 Jan 30].
- Denkert С., von Minckwitz G., Darb-Esfahani S., et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet. Oncol. 2018;19:40-50. Doi: 10.1016/ S1470-2045(17)30904-X.
- Luen S., Solgado R., Died M., et al. Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple negative breast cancer patients after neoadjuvant chemotherapy. Ann Oncol. 2019;30(2):236-42. Doi: https://doi.org/10.1093/annonc/mdy547.
- Loi S., Dmbay D., Adams S., et al. Pooled individual patient data analysis of stromal tumor infiltrating lymphocytes in primary triple negative breast cancer treated with anthracycline-based chemotherapy. Cancer Res. 2016;76:Abstract S 1-03. Doi: 10.1200/ JCO.18.01010.
- Dieci M.V., Criscitiello C., Goubar A., et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;25:611-823. doi: 10.1093/annonc/ mdt556.
- CrisctielJo С, Bny ar M.A., Curigliano G., et al. A gene signature to predict hightumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer. Ann Oncol. 2018;29:162-69. doi: 10.1093/ annonc/mdx691.
- Haitmann L, Schaid D., Woods J., Crotty T., Myers J. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. Engl J Med. 1999;340(2):77-84. Doi: 10.1056/ NEJM199901143400201.
- Phillips K.A., Lindeman G.J. Breast cancer prevention for BRCA1 and BRCA2 mutation carriers: is there a role for tamoxifen? Future Oncol. 2014;10(4):499-502. doi.org/10.2217/fon.13.278
- Fisher В., Costantino J.P, Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 2005;97:1652-62. doi: 10.1093/jnci/dji372.
- Cuzick J., Sestak I., Bonanni B., et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual. Lancet. 2013;381(9880):1827-34. doi: 10.1016/S0140-6736(13)60140-3.
- Metcalfe K., Lynch H.T., Ghadirian P., et al. Contralateral breast cancer in BRCAl and BRCA2 mutation carriers. J Clin Oncol. 2004;22(12):2328-35. Doi: 10.1200/ JCO.2004.04.033.
- Narod S.A. Hormonal prevention of hereditary breast cancer. Ann N Y Acad Sci. 2001;952:36-43. Doi. org/10.1111/j.1749-6632.2001.tb02726.x
- Farmer H. McCabe N., Lord C.J., et al: Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917-21. https://doi.org/10.1038/nature03445
- Robson M., Im S.A., Senkus E., et al: Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523-33. doi: 10.1056/NEJMoa1706450.
- Litton J.K., Rugo H.S., Ettl J., et al: Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753-63. doi: 10.1056/NEJMoa1802905.
- Ettl J., Quek R.G.W., lee K.H., et al: Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: Patient-reported outcomes from the EMBRACA phase III trial. Ann. Oncol. 2018;29:1939-47. doi: 10.1090/annonc/mdy257.
- Burstein H.L., Curigliano G., toibl S., et al. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019;00(10):1541-57. Doi: 10.1093/ annonc/mdz235.
- Loibl S., Weber K.E., Timms K.M., et al. Survival analysis of carboplatin added to an anthracycline/taxanebased neoadjuvant chemotherapy and HRD score as predictor of responsefinal results from GeparSixto. Ann Oncol. 2018;29(12):2041-47. Doi: 10.1093/ annonc/mdy460.
- hoibl S., Untch M.N., et al. Randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). J Clin Oncol 2018;36(suppl):abstr 104. doi: 10.1200/JCO.2018.36.15_suppl.104.
- Nanda R., Liu M.C., Yau C., et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (ВС): results from I-SPY2. J Clin Oncol. 2017;35(l5):S506-6. Doi: 10.1200/ JCO.2017.35.15_suppl.506.
- Martin M., Barrios C.H., Torrecilla L., et al. Efficacy results form the CIBOMA 2004-01/ GEICAM 200311 study: a randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer. SABCS. 2018. doi: 10.1158/1538-7445.SABCS18-GS2-04.
- Nitz U., Gluk O., Clegpens М., et al. West German PlanB Trial: adjuvant four cycles of epirubicin and cyclophosphamide plus docetaxel versus six cycles of docetaxel and cyclophosphamide in HER2 negative early breast cancer. J Clin Oncol. 2019;37:799-808. doi: 10.1200/JCO.18.00028.
- Blum J.L., Flynn PJ., Yothers G., et al. Anthracyclines in early breast cancer: the ABC Trials USOR 06-090, NSABP B-46-1/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol. 2017;35:2647-55. doi: 10.1200/JCO.2016.71.4147.
- Robson М., Im S.A., Senkus Е., et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523-33. doi: 10.1056/NEJMoa1706450.
- Weigelt В., Comino-Mndez I., de Bruijn I., et al. Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer. Clin. Cancer Res. 2017;23(21):6708-20. doi: 10.1158/1078-0432.CCR-17-0544.
- Kurian A.W., Ward К.С., Howlader N. Genetic Testing and Results in a Population- Based Cohort of Breast Cancer Patients and Ovarian Cancer Patients. J Clin Oncol. 2019;07(15):1005-15. Doi: 10.1200/ JCO.18.01854.